These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11947912)

  • 1. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease.
    Seljeflot I; Tonstad S; Hjermann I; Arnesen H
    Atherosclerosis; 2002 May; 162(1):179-85. PubMed ID: 11947912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
    Patti G; Chello M; Pasceri V; Colonna D; Nusca A; Miglionico M; D'Ambrosio A; Covino E; Di Sciascio G
    J Am Coll Cardiol; 2006 Oct; 48(8):1560-6. PubMed ID: 17045888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?
    Valkonen VP; Laakso J; Päivä H; Lehtimäki T; Lakka TA; Isomustajärvi M; Ruokonen I; Salonen JT; Laaksonen R
    Atheroscler Suppl; 2003 Dec; 4(4):19-22. PubMed ID: 14664898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
    Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V
    Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
    Karalis DG; Ross AM; Vacari RM; Zarren H; Scott R
    Am J Cardiol; 2002 Mar; 89(6):667-71. PubMed ID: 11897207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers.
    Seljeflot I; Arnesen H; Brude IR; Nenseter MS; Drevon CA; Hjermann I
    Eur J Clin Invest; 1998 Aug; 28(8):629-35. PubMed ID: 9767357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
    Bays HE; Stein EA; Shah AK; Maccubbin DL; Mitchel YB; Mercuri M
    Am J Cardiol; 2002 Nov; 90(9):942-6. PubMed ID: 12398959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease.
    Alber HF; Frick M; Süssenbacher A; Dörler J; Dichtl W; Stocker EM; Pachinger O; Weidinger F
    Wien Med Wochenschr; 2007 Feb; 157(3-4):73-8. PubMed ID: 17340064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
    Seljeflot I; Tonstad S; Hjermann I; Arnesen H
    Thromb Res; 2002 Feb; 105(4):285-90. PubMed ID: 12031821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of soluble cell adhesion molecules in patients with dyslipidemia.
    Hackman A; Abe Y; Insull W; Pownall H; Smith L; Dunn K; Gotto AM; Ballantyne CM
    Circulation; 1996 Apr; 93(7):1334-8. PubMed ID: 8641021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand.
    Stach K; Nguyen XD; Lang S; Elmas E; Weiss C; Borggrefe M; Fischer J; Kälsch T
    Cardiol J; 2012; 19(1):20-8. PubMed ID: 22298164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study.
    Porta B; Baldassarre D; Camera M; Amato M; Arquati M; Brusoni B; Fiorentini C; Montorsi P; Romano S; Tremoli E; Cortellaro M;
    Nutr Metab Cardiovasc Dis; 2008 May; 18(4):320-8. PubMed ID: 17889518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
    Freed MI; Ratner R; Marcovina SM; Kreider MM; Biswas N; Cohen BR; Brunzell JD;
    Am J Cardiol; 2002 Nov; 90(9):947-52. PubMed ID: 12398960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.